Workflow
昊海生科: 上海昊海生物科技股份有限公司关于第二期A股股份回购实施结果公告
Zheng Quan Zhi Xing·2025-08-15 16:35

Core Viewpoint - The company has successfully completed its second phase of A-share repurchase, acquiring a total of 1,832,421 shares, which represents 0.79% of its total share capital, with a total expenditure of approximately 103.91 million yuan [1][3][4]. Summary by Sections Repurchase Plan and Approval - The repurchase plan was first disclosed on August 17, 2024, with a total expected repurchase amount between 100 million yuan and 200 million yuan, and a maximum repurchase price of 89.71 yuan per share [1]. - The board approved the repurchase on August 16, 2024, and the implementation period is from August 16, 2024, to August 15, 2025 [1]. Adjustments to Repurchase Price - Following the implementation of the 2024 semi-annual equity distribution, the maximum repurchase price was adjusted from 89.71 yuan to 89.31 yuan per share [2]. - After the 2024 annual equity distribution, the maximum repurchase price was further adjusted to 88.72 yuan per share [2]. Implementation Status - The company initiated the repurchase on November 26, 2024, and completed the repurchase by August 14, 2025, acquiring a total of 1,832,421 shares at an average price of 56.70 yuan per share [3][4]. - The total funds used for the repurchase amounted to approximately 103.91 million yuan, excluding taxes and transaction fees [3]. Share Distribution Changes - Prior to the repurchase, the total share count was 235,489,895 shares, which decreased to 232,581,095 shares post-repurchase [4][5]. - The repurchased shares will be used for employee stock ownership plans or equity incentives and will not enjoy voting rights or profit distribution during the holding period [6]. Future Plans for Repurchased Shares - The repurchased shares are intended to be transferred within three years; if not transferred, they will be canceled and the registered capital will be reduced accordingly [6].